Compare QIPT & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QIPT | GANX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | QIPT | GANX |
|---|---|---|
| Price | $3.58 | $1.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.83 | ★ $8.00 |
| AVG Volume (30 Days) | 438.2K | ★ 651.9K |
| Earning Date | 02-09-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $264,974,000.00 | N/A |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.28 | N/A |
| 52 Week Low | $1.35 | $1.41 |
| 52 Week High | $3.61 | $4.34 |
| Indicator | QIPT | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 71.93 | 40.89 |
| Support Level | $3.55 | $1.67 |
| Resistance Level | $3.54 | $1.86 |
| Average True Range (ATR) | 0.02 | 0.13 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 87.50 | 46.15 |
Quipt Home Medical Corp is a provider of durable medical equipment (DME) and home medical equipment (HME) in the United States. The Company specializes in delivering in-home treatments for the management of chronic conditions, with a primary focus on respiratory diseases, and supports patients with heart and pulmonary diseases, sleep apnea, reduced mobility, and other chronic health challenges. Its products and services include Sleep Apnea and PAP treatment, home medical equipment, home ventilation, and custom mobility solutions. The Company operates in a single business segment, comprising the sale and rental of medical equipment and related devices, and serves patients across 27 states in the United States.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.